Minlu Zhang
Overview
Explore the profile of Minlu Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
697
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Q, Fan Y, Liu X, Zhang M, Zhang J, Du Q, et al.
J Diabetes Investig
. 2025 Feb;
PMID: 39899440
Aims: To evaluate characteristics and glycemic outcomes in individuals with type 2 diabetes using injectable therapies in real-world clinical practice in Tianjin, China. Materials And Methods: Data from inpatients and...
2.
Chen L, Wan H, Han J, Yang C, Shao H, Li J, et al.
Diabetes Obes Metab
. 2024 Dec;
27(3):1423-1431.
PMID: 39691971
Aims: To evaluate the efficacy and safety of insulin glargine 300 U/mL (Gla-300) in people with uncontrolled type 2 diabetes (T2D) switching from another basal insulin (BI). Materials And Methods:...
3.
Zhang Q, Fan Y, Liu X, Zhang M, Zhang J, Du Q, et al.
Diabetes Ther
. 2024 Nov;
16(1):1-14.
PMID: 39487283
Introduction: Diabetes is associated with a high economic burden in China; therefore, strategies to prevent diabetes, improve glycaemic control, delay disease-related complications and maintain quality of life are essential. This...
4.
Yuan X, Li D, Wang K, Lauand F, Zhang M, Fang H, et al.
Diabetes Obes Metab
. 2024 Oct;
26(12):5942-5949.
PMID: 39360440
Aim: To compare the effects of iGlarLixi versus insulin glargine 100 U/mL (iGlar) on residual hyperglycaemia in Chinese people with uncontrolled type 2 diabetes (T2D) on prior basal insulin (BI)...
5.
Chen L, Wen B, Liu H, Wu H, Duan B, Shu H, et al.
Diabetes Obes Metab
. 2024 Jul;
26(10):4571-4582.
PMID: 39075925
Aim: To evaluate the efficacy and safety of insulin glargine 300 U/mL (Gla-300) in people with suboptimally controlled type 2 diabetes (T2D) in China. Methods: INITIATION (NCT05002933) was a prospective,...
6.
Girard B, Baum-Jones E, Best R, Campbell T, Coupart J, Dangerfield K, et al.
Front Immunol
. 2024 Apr;
15:1285278.
PMID: 38562934
Background: Characterizing the antibody epitope profiles of messenger RNA (mRNA)-based vaccines against SARS-CoV-2 can aid in elucidating the mechanisms underlying the antibody-mediated immune responses elicited by these vaccines. Methods: This...
7.
Klein J, Wood J, Jaycox J, Dhodapkar R, Lu P, Gehlhausen J, et al.
Nature
. 2023 Sep;
623(7985):139-148.
PMID: 37748514
Post-acute infection syndromes may develop after acute viral disease. Infection with SARS-CoV-2 can result in the development of a post-acute infection syndrome known as long COVID. Individuals with long COVID...
8.
Wang T, Zhu X, Chen Y, Shen S, Tang Y, Zhang J, et al.
Drugs R D
. 2023 May;
23(2):129-140.
PMID: 37165291
Introduction: Despite rasburicase's proven efficiency in Caucasians, Japanese, and Koreans, studies evaluating the safety and effectiveness of rasburicase in Chinese pediatric patients with non-Hodgkin's lymphoma (NHL) and acute leukemia (AL)...
9.
Jiang T, Li A, Zhang M, Zhou Z, Wang L, Zhang X, et al.
Adv Ther
. 2023 Mar;
40(5):2562.
PMID: 36967441
No abstract available.
10.
Yao J, Zhang M, Zhang X, Zhang J
Diabetes Ther
. 2023 Feb;
14(4):653-669.
PMID: 36809495
Introduction: This analysis investigated the efficacy and safety of add-on lixisenatide by disease duration in Asian people with type 2 diabetes inadequately controlled with basal insulin ± oral antidiabetic drugs....